Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

M. Aoudjhane, M. Labopin, N. C. Gorin, A. Shimoni, T. Ruutu, H. J. Kolb, F. Frassoni, J. M. Boiron, J. L. Yin, J. Finke, H. Shouten, D. Blaise, M. Falda, A. A. Fauser, J. Esteve, E. Polge, S. Slavin, D. Niederwieser, A. Nagler, Vanderson RochaP. Galiene, M. Petrini, G. Schlimok, A. Buzyn, E. Ovali, A. Gratwohl, R. Willemze, D. Bunjes, J. M. Goldman, N. Jacobsen, E. Gluckman, U. Schanz, M. A. Boogaerts, P. Ljungman, E. Montserrat, D. Bron, M. Potter, A. Bacigalupo, R. Powles, B. Rio, L. Kanz, A. H. Goldstone, K. Remes, H. T. Greinix, J. M. Davies, D. Blaise, M. Falda, F. Mandelli, J. Y. Cahn, A. Ferrant, L. Brinch, J. M. Fernández-Ranada, A. Torres Gomez, L. F. Verdonck, M. Baccarani, A. Iriondo, I. Franklin, V. Rizzoli, J. J. Cornelissen, H. Van den Berg, C. Cordonnier, J. L. Harousseau, D. L. Barnard, T. Littlewood, H. A. Horst, S. McCann, S. Slavin, U. W. Schaefer, J. Sierra, B. Chapuis, V. Leblond, F. Guilhot, G. Lambertenghi Deliliers, B. Simonsson, J. Reiffers, J. J. Sotto, G. Gastl, J. O. Bay, G. L. Jackson, J. García-Conde, S. Lenhoff, E. P. Alessandrino, I. Majolino, T. Izzi, M. Brune, P. Pimentel, W. Siegert, E. Morra, B. Hertenstein, D. Hoelzer, P. Coser, M. Abecasis, B. Labar, A. K. Burnett, A. Bosi, G. Leone, W. Linkesch, R. Schwerdtfeger, F. Lauria

Research output: Contribution to journalArticle

336 Citations (Scopus)

Abstract

Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%;) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II -IV) and transplant-related mortality were significantly decreased (P=0.01 and P-4, respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.

Original languageEnglish
Pages (from-to)2304-2312
Number of pages9
JournalLeukemia
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Hematopoietic Stem Cell Transplantation
Blood Group Antigens
Acute Myeloid Leukemia
Siblings
Leukemia
Transplantation
Bone Marrow
Transplantation Conditioning
Multivariate Analysis
Transplants
Busulfan
Whole-Body Irradiation
Cytogenetics
Surveys and Questionnaires
Conditioning (Psychology)
Recurrence
Survival
Mortality
Incidence

Keywords

  • Acute myelocytic leukemia
  • Genmoidentical haematopoitic stem cell transplants
  • Reduced intensity preparative regimen

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia : A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). / Aoudjhane, M.; Labopin, M.; Gorin, N. C.; Shimoni, A.; Ruutu, T.; Kolb, H. J.; Frassoni, F.; Boiron, J. M.; Yin, J. L.; Finke, J.; Shouten, H.; Blaise, D.; Falda, M.; Fauser, A. A.; Esteve, J.; Polge, E.; Slavin, S.; Niederwieser, D.; Nagler, A.; Rocha, Vanderson; Galiene, P.; Petrini, M.; Schlimok, G.; Buzyn, A.; Ovali, E.; Gratwohl, A.; Willemze, R.; Bunjes, D.; Goldman, J. M.; Jacobsen, N.; Gluckman, E.; Schanz, U.; Boogaerts, M. A.; Ljungman, P.; Montserrat, E.; Bron, D.; Potter, M.; Bacigalupo, A.; Powles, R.; Rio, B.; Kanz, L.; Goldstone, A. H.; Remes, K.; Greinix, H. T.; Davies, J. M.; Blaise, D.; Falda, M.; Mandelli, F.; Cahn, J. Y.; Ferrant, A.; Brinch, L.; Fernández-Ranada, J. M.; Torres Gomez, A.; Verdonck, L. F.; Baccarani, M.; Iriondo, A.; Franklin, I.; Rizzoli, V.; Cornelissen, J. J.; Van den Berg, H.; Cordonnier, C.; Harousseau, J. L.; Barnard, D. L.; Littlewood, T.; Horst, H. A.; McCann, S.; Slavin, S.; Schaefer, U. W.; Sierra, J.; Chapuis, B.; Leblond, V.; Guilhot, F.; Lambertenghi Deliliers, G.; Simonsson, B.; Reiffers, J.; Sotto, J. J.; Gastl, G.; Bay, J. O.; Jackson, G. L.; García-Conde, J.; Lenhoff, S.; Alessandrino, E. P.; Majolino, I.; Izzi, T.; Brune, M.; Pimentel, P.; Siegert, W.; Morra, E.; Hertenstein, B.; Hoelzer, D.; Coser, P.; Abecasis, M.; Labar, B.; Burnett, A. K.; Bosi, A.; Leone, G.; Linkesch, W.; Schwerdtfeger, R.; Lauria, F.

In: Leukemia, Vol. 19, No. 12, 12.2005, p. 2304-2312.

Research output: Contribution to journalArticle

Aoudjhane, M, Labopin, M, Gorin, NC, Shimoni, A, Ruutu, T, Kolb, HJ, Frassoni, F, Boiron, JM, Yin, JL, Finke, J, Shouten, H, Blaise, D, Falda, M, Fauser, AA, Esteve, J, Polge, E, Slavin, S, Niederwieser, D, Nagler, A, Rocha, V, Galiene, P, Petrini, M, Schlimok, G, Buzyn, A, Ovali, E, Gratwohl, A, Willemze, R, Bunjes, D, Goldman, JM, Jacobsen, N, Gluckman, E, Schanz, U, Boogaerts, MA, Ljungman, P, Montserrat, E, Bron, D, Potter, M, Bacigalupo, A, Powles, R, Rio, B, Kanz, L, Goldstone, AH, Remes, K, Greinix, HT, Davies, JM, Blaise, D, Falda, M, Mandelli, F, Cahn, JY, Ferrant, A, Brinch, L, Fernández-Ranada, JM, Torres Gomez, A, Verdonck, LF, Baccarani, M, Iriondo, A, Franklin, I, Rizzoli, V, Cornelissen, JJ, Van den Berg, H, Cordonnier, C, Harousseau, JL, Barnard, DL, Littlewood, T, Horst, HA, McCann, S, Slavin, S, Schaefer, UW, Sierra, J, Chapuis, B, Leblond, V, Guilhot, F, Lambertenghi Deliliers, G, Simonsson, B, Reiffers, J, Sotto, JJ, Gastl, G, Bay, JO, Jackson, GL, García-Conde, J, Lenhoff, S, Alessandrino, EP, Majolino, I, Izzi, T, Brune, M, Pimentel, P, Siegert, W, Morra, E, Hertenstein, B, Hoelzer, D, Coser, P, Abecasis, M, Labar, B, Burnett, AK, Bosi, A, Leone, G, Linkesch, W, Schwerdtfeger, R & Lauria, F 2005, 'Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)', Leukemia, vol. 19, no. 12, pp. 2304-2312. https://doi.org/10.1038/sj.leu.2403967
Aoudjhane, M. ; Labopin, M. ; Gorin, N. C. ; Shimoni, A. ; Ruutu, T. ; Kolb, H. J. ; Frassoni, F. ; Boiron, J. M. ; Yin, J. L. ; Finke, J. ; Shouten, H. ; Blaise, D. ; Falda, M. ; Fauser, A. A. ; Esteve, J. ; Polge, E. ; Slavin, S. ; Niederwieser, D. ; Nagler, A. ; Rocha, Vanderson ; Galiene, P. ; Petrini, M. ; Schlimok, G. ; Buzyn, A. ; Ovali, E. ; Gratwohl, A. ; Willemze, R. ; Bunjes, D. ; Goldman, J. M. ; Jacobsen, N. ; Gluckman, E. ; Schanz, U. ; Boogaerts, M. A. ; Ljungman, P. ; Montserrat, E. ; Bron, D. ; Potter, M. ; Bacigalupo, A. ; Powles, R. ; Rio, B. ; Kanz, L. ; Goldstone, A. H. ; Remes, K. ; Greinix, H. T. ; Davies, J. M. ; Blaise, D. ; Falda, M. ; Mandelli, F. ; Cahn, J. Y. ; Ferrant, A. ; Brinch, L. ; Fernández-Ranada, J. M. ; Torres Gomez, A. ; Verdonck, L. F. ; Baccarani, M. ; Iriondo, A. ; Franklin, I. ; Rizzoli, V. ; Cornelissen, J. J. ; Van den Berg, H. ; Cordonnier, C. ; Harousseau, J. L. ; Barnard, D. L. ; Littlewood, T. ; Horst, H. A. ; McCann, S. ; Slavin, S. ; Schaefer, U. W. ; Sierra, J. ; Chapuis, B. ; Leblond, V. ; Guilhot, F. ; Lambertenghi Deliliers, G. ; Simonsson, B. ; Reiffers, J. ; Sotto, J. J. ; Gastl, G. ; Bay, J. O. ; Jackson, G. L. ; García-Conde, J. ; Lenhoff, S. ; Alessandrino, E. P. ; Majolino, I. ; Izzi, T. ; Brune, M. ; Pimentel, P. ; Siegert, W. ; Morra, E. ; Hertenstein, B. ; Hoelzer, D. ; Coser, P. ; Abecasis, M. ; Labar, B. ; Burnett, A. K. ; Bosi, A. ; Leone, G. ; Linkesch, W. ; Schwerdtfeger, R. ; Lauria, F. / Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia : A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). In: Leukemia. 2005 ; Vol. 19, No. 12. pp. 2304-2312.
@article{344391e815674a38b6dfd169d03f934d,
title = "Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)",
abstract = "Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53{\%};) or low-dose total body irradiation (24{\%}). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II -IV) and transplant-related mortality were significantly decreased (P=0.01 and P-4, respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.",
keywords = "Acute myelocytic leukemia, Genmoidentical haematopoitic stem cell transplants, Reduced intensity preparative regimen",
author = "M. Aoudjhane and M. Labopin and Gorin, {N. C.} and A. Shimoni and T. Ruutu and Kolb, {H. J.} and F. Frassoni and Boiron, {J. M.} and Yin, {J. L.} and J. Finke and H. Shouten and D. Blaise and M. Falda and Fauser, {A. A.} and J. Esteve and E. Polge and S. Slavin and D. Niederwieser and A. Nagler and Vanderson Rocha and P. Galiene and M. Petrini and G. Schlimok and A. Buzyn and E. Ovali and A. Gratwohl and R. Willemze and D. Bunjes and Goldman, {J. M.} and N. Jacobsen and E. Gluckman and U. Schanz and Boogaerts, {M. A.} and P. Ljungman and E. Montserrat and D. Bron and M. Potter and A. Bacigalupo and R. Powles and B. Rio and L. Kanz and Goldstone, {A. H.} and K. Remes and Greinix, {H. T.} and Davies, {J. M.} and D. Blaise and M. Falda and F. Mandelli and Cahn, {J. Y.} and A. Ferrant and L. Brinch and Fern{\'a}ndez-Ranada, {J. M.} and {Torres Gomez}, A. and Verdonck, {L. F.} and M. Baccarani and A. Iriondo and I. Franklin and V. Rizzoli and Cornelissen, {J. J.} and {Van den Berg}, H. and C. Cordonnier and Harousseau, {J. L.} and Barnard, {D. L.} and T. Littlewood and Horst, {H. A.} and S. McCann and S. Slavin and Schaefer, {U. W.} and J. Sierra and B. Chapuis and V. Leblond and F. Guilhot and {Lambertenghi Deliliers}, G. and B. Simonsson and J. Reiffers and Sotto, {J. J.} and G. Gastl and Bay, {J. O.} and Jackson, {G. L.} and J. Garc{\'i}a-Conde and S. Lenhoff and Alessandrino, {E. P.} and I. Majolino and T. Izzi and M. Brune and P. Pimentel and W. Siegert and E. Morra and B. Hertenstein and D. Hoelzer and P. Coser and M. Abecasis and B. Labar and Burnett, {A. K.} and A. Bosi and G. Leone and W. Linkesch and R. Schwerdtfeger and F. Lauria",
year = "2005",
month = "12",
doi = "10.1038/sj.leu.2403967",
language = "English",
volume = "19",
pages = "2304--2312",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia

T2 - A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

AU - Aoudjhane, M.

AU - Labopin, M.

AU - Gorin, N. C.

AU - Shimoni, A.

AU - Ruutu, T.

AU - Kolb, H. J.

AU - Frassoni, F.

AU - Boiron, J. M.

AU - Yin, J. L.

AU - Finke, J.

AU - Shouten, H.

AU - Blaise, D.

AU - Falda, M.

AU - Fauser, A. A.

AU - Esteve, J.

AU - Polge, E.

AU - Slavin, S.

AU - Niederwieser, D.

AU - Nagler, A.

AU - Rocha, Vanderson

AU - Galiene, P.

AU - Petrini, M.

AU - Schlimok, G.

AU - Buzyn, A.

AU - Ovali, E.

AU - Gratwohl, A.

AU - Willemze, R.

AU - Bunjes, D.

AU - Goldman, J. M.

AU - Jacobsen, N.

AU - Gluckman, E.

AU - Schanz, U.

AU - Boogaerts, M. A.

AU - Ljungman, P.

AU - Montserrat, E.

AU - Bron, D.

AU - Potter, M.

AU - Bacigalupo, A.

AU - Powles, R.

AU - Rio, B.

AU - Kanz, L.

AU - Goldstone, A. H.

AU - Remes, K.

AU - Greinix, H. T.

AU - Davies, J. M.

AU - Blaise, D.

AU - Falda, M.

AU - Mandelli, F.

AU - Cahn, J. Y.

AU - Ferrant, A.

AU - Brinch, L.

AU - Fernández-Ranada, J. M.

AU - Torres Gomez, A.

AU - Verdonck, L. F.

AU - Baccarani, M.

AU - Iriondo, A.

AU - Franklin, I.

AU - Rizzoli, V.

AU - Cornelissen, J. J.

AU - Van den Berg, H.

AU - Cordonnier, C.

AU - Harousseau, J. L.

AU - Barnard, D. L.

AU - Littlewood, T.

AU - Horst, H. A.

AU - McCann, S.

AU - Slavin, S.

AU - Schaefer, U. W.

AU - Sierra, J.

AU - Chapuis, B.

AU - Leblond, V.

AU - Guilhot, F.

AU - Lambertenghi Deliliers, G.

AU - Simonsson, B.

AU - Reiffers, J.

AU - Sotto, J. J.

AU - Gastl, G.

AU - Bay, J. O.

AU - Jackson, G. L.

AU - García-Conde, J.

AU - Lenhoff, S.

AU - Alessandrino, E. P.

AU - Majolino, I.

AU - Izzi, T.

AU - Brune, M.

AU - Pimentel, P.

AU - Siegert, W.

AU - Morra, E.

AU - Hertenstein, B.

AU - Hoelzer, D.

AU - Coser, P.

AU - Abecasis, M.

AU - Labar, B.

AU - Burnett, A. K.

AU - Bosi, A.

AU - Leone, G.

AU - Linkesch, W.

AU - Schwerdtfeger, R.

AU - Lauria, F.

PY - 2005/12

Y1 - 2005/12

N2 - Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%;) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II -IV) and transplant-related mortality were significantly decreased (P=0.01 and P-4, respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.

AB - Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%;) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II -IV) and transplant-related mortality were significantly decreased (P=0.01 and P-4, respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.

KW - Acute myelocytic leukemia

KW - Genmoidentical haematopoitic stem cell transplants

KW - Reduced intensity preparative regimen

UR - http://www.scopus.com/inward/record.url?scp=28644452432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644452432&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403967

DO - 10.1038/sj.leu.2403967

M3 - Article

C2 - 16193083

AN - SCOPUS:28644452432

VL - 19

SP - 2304

EP - 2312

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -